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ABSTRACT 
Malaria-endemic areas of the world are noted for high morbidity and mortality from malaria. Also noted in these areas 
is the majority of persons in the population having acquired malaria immunity. Though this acquired malaria immunity 
does not prevent infection, it resists the multiplication of Plasmodium parasites, restricting disease to merely uncom-
plicated cases or asymptomatic infections. Does this acquired malaria immunity in endemic areas protect against other 
diseases, especially outbreak diseases like COVID-19? Does malaria activation of innate immunity resulting in trained 
or tolerance immunity contribute to protection against COVID-19?  In an attempt to answer these questions, this 
review highlights the components of malaria and viral immunity and explores possible links with immunity against 
COVID-19. With malaria-endemic areas of the world having a fair share of cases of COVID-19, it is important to 
direct research in this area to evaluate and harness any benefits of acquired malaria immunity to help mitigate the 
effects of COVID-19 and any possible future outbreaks.  
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INTRODUCTION 
Malaria, caused by the Plasmodium parasite, is an en-
demic disease found in most tropical countries, where en-
vironmental and socioeconomic factors foster its peren-
nial persistence.1 In sub-Saharan Africa, malaria is a se-
rious public health concern because the region bears a 
disproportionately high burden of global malaria morbid-
ity and mortality, responsible for about  93% of the 228 
million cases and  94% of 411,000 deaths globally in 
2018.1 While everyone living in these endemic areas is at 
risk of falling ill or dying from malaria. Its impact is seen 
more among the vulnerable population, such as pregnant 
women and young children.1  
 
Despite the high burden of malaria in these endemic ar-
eas, there is some level of malaria immunity among most 
of the population, acquired through a precarious, re-
peated lifelong encounter with the Plasmodium para-
site.2,3 This malaria immunity is seen mainly among the 
population's non-pregnant adults, resulting in the mild or 
asymptomatic presentation of the disease among this 
group2, thus shifting the bulk of the morbidity and mor-
tality to children and pregnant women.1 Apart from the 
acquired immunity from malaria actively preventing the 
severe outcomes of malaria, it is pertinent to ask if this 
immunity observed among the vast majority of the popu-
lation living in malaria-endemic areas could also offer 
protection against other infectious diseases, such as 
COVID-19. 
 
COVID-19 is a viral disease caused by a novel type of 
coronavirus called severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).4 It is an ongoing pan-
demic affecting all countries globally, including malaria-
endemic countries in sub-Saharan Africa.5 The global 
figures for COVID-19 as of December 17th 2020, were 
over 74 million with over 1.5 million deaths and over 42 
million recoveries. For Africa was over two million with 
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There are several schools of thought for the relatively 
lower number of cases recorded in Africa, including in-
adequate testing of suspected cases and the prevailing 
warmer climate conditions.7,8 To date, no country within 
the malaria-endemic zone of Africa (i.e. West, Central 
and East Africa) has experienced sporadic spikes in mor-
tality as observed in Europe, the Americas and the north-
ern and southern parts of Africa. Could immunity to ma-
laria, which is a predominant feature in these endemic ar-
eas, contribute to the low numbers of infections, faster 
clearance of the virus, milder presentation and low mor-
tality observed so far? This brief review seeks to assess 
the possible role of malaria immunity in mitigating the 
impact of COVID-19 in malaria-endemic areas. This pa-
per reviews the mechanisms of immune response to ma-
laria and the dynamics of developing malaria immunity. 
We additionally review the basics of developing immun-
ity against viruses, especially the coronaviruses and ex-
amine the dynamics of Plasmodium and viral coinfec-
tions, highlighting a possible relationship between ac-
quired malaria immunity and coronavirus immunity.  
 
Developing Malaria Immunity  
Malaria immunity is a complex phenomenon, an evolv-
ing topic yet to be fully understood.2,9 It is said to be a 
state of resistance to the Plasmodium parasite acquired 
through the repeated activities involving the clearance 
and restriction of the multiplication of the parasite.9 This 
acquired immunity begins as clinical immunity or anti-
disease immunity and effectively prevents the manifesta-
tion of symptoms within a given threshold of para-
sitemia.2,9,10 This means that, beyond a given threshold of 
parasite load, clinical immunity will fail.9 This type of 
acquired malaria immunity is first developed in child-
hood.9,11 The other type of acquired malaria immunity is 
the anti-parasite immunity responsible for direct parasite 
clearance with resultant decreasing parasite load. This is 
the major effective malaria immunity possessed by adults 
who have lived most of their lives in malaria-endemic ar-
eas.9  
 
In holoendemic malarious areas, people are repeatedly 
exposed to malaria infection from childhood and well 
into adulthood,  with children manifesting more disease 
symptoms than adults.9,3,10 When a child is born in a hol-
oendemic area, their risk of malaria infections is rela-
tively low within the first six months of life through the 
protection from the passively-acquired immunity from 
placental transfer of maternal immunoglobin G.9,10,11 
This passive immunity dwindles with age and the risk of 
disease and death increases.9 Through repeated exposure 
to sub-lethal infections, the child eventually develops ac-
tive immunity from around two years.9 This immunity 
peaks around the age of puberty and gets sustained by 
subsequent repeated infections.9  
Asymptomatic infection is the predominant presentation 
seen in patients with malaria immunity and is believed to 
confer some form of immunity through premunition.9,10 
It is important to state categorically that this immunity is 
non-sterilizing and can be lost if there is no exposure to 
infection for 3-5 years.9,10,12  
 
Mechanism of Immune Response to Malaria 
The immunity against malaria is quite complex but 
mainly targets the asexual forms of the parasite employ-
ing a timely relay between antibody and cell-mediated 
immunity.9,12 Malaria immunity characteristically begins 
with an innate immune response involving macrophages, 
dendritic cells and natural killer cells resulting in a sharp 
burst of pro-inflammatory cytokines that induce inflam-
mation to restrict parasite growth.9,12 These pro-inflam-
matory cytokines must be regulated by anti-inflammatory 
cytokines because they can lead to severe malaria and 
death when unregulated.9,12  This is followed by activa-
tion of the CD4 cells with subsequent clonal expansion 
producing Th1 and Th2, resulting in cell-mediated and an-
tibody-mediated immunities, respectively.9,12 Th2 CD4 
cells activate B cells to produce antibodies, especially 
immunoglobin G, which play pivotal roles in the immun-
ity against the parasite.2,9,12 Antibodies produced target 
free circulating merozoites and parasitized red blood 
cells (RBCs), preventing merozoites invasion of (RBCs) 
and the cytoadherence of parasitized RBCs on the endo-
thelium.9 This attachment of the antibodies to the mero-
zoites and parasitized RBCs could result in any of the fol-
lowing: opsonization and subsequent phagocytosis, com-
plement-mediated cell destruction or antibody-dependent 
cell-mediated destruction of parasitized RBCs.9,12 Immu-
noglobin G is the major antibody that triggers this cas-
cade of immune reactions. In some malaria-endemic ar-
eas, high levels of circulating immunoglobin G have been 
linked to lower malaria risks.12,13,14 Th1 promotes cell-
mediated immunity by aiding macrophages in the de-
struction of parasitized RBCs.12 
 
Natural killer cells are activated in malaria infection, a 
finding seen among infected children in endemic ar-
eas.12,15,16 They are involved in the direct destruction of 
parasitized RBCs and the production of pro-inflamma-
tory cytokines like interferon gamma.12,17 This occurs 
early in malaria infection, even before activation of CD4 
cells.12 Interferon gamma has been linked with resistance 
to malaria infection, milder diseases in children and also 
prevention of reinfection in children within a year of mild 
infections.17,18,19 Interferon alpha and beta, collectively 
referred to as type 1 interferon also play an important role 
in malaria immunity by regulating the pro-inflammatory 
function of interferon gamma, thereby preventing an un-
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After the immune cells and their products (cytokines and 
antibodies) are produced during an immune response to 
malaria, they can linger for years as memory cells and as 
circulating cytokines and antibodies if sustained by re-
peated infections.9,12,17 Though natural killer cells have 
been considered part of innate immunity, and recent find-
ings suggest a capacity to retain memory and elicit a 
memory-like response.17,21   
 
Immunity against Viruses 
Like the immunity against malaria, immunity against vi-
ruses begins with innate immunity and chiefly involves 
dendritic cells, natural killer cells and pro-inflammatory 
cytokines, especially interferons.22,23 The interferons play 
a significant role in antiviral immunity. The name inter-
feron derives from their ability to “interfere” with viral 
replication. The three major types, namely, types 1, 2 and 
3 interferons, are all involved in antiviral immunity with 
type 2, also called interferon gamma, additionally play-
ing a major role in immunity against malaria. While type 
1 and type 3 are produced by infected host cells, inter-
feron gamma is produced by immune cells like natural 
killer cells and the CD8- and CD4-bearing T-cells.24 In-
terferon gamma plays a complex and vital immune mod-
ulatory function regulating the actions of other interfer-
ons and cytokines and cellular immunity.24,25 Its activity 
in inhibiting the growth of both DNA and RNA viruses 
is evidenced by the decreased multiplication of the Vari-
cella-Zoster virus within infected neurons resulting in the 
improved survival of the neurons.26 Interferon gamma 
also impedes the growth and multiplication of the Hepa-
titis C virus within infected hepatocytes.27 It decreases 
the multiplication of SARS-CoV,  the coronavirus re-
sponsible SARS outbreak of 2003.28,29 Cytokine analyses 
of patients with SARS showed interferon gamma's pres-
ence at the early stages of the infection resulted in early 
resolution of the symptoms.30  Interferon therapy is con-
sequently under evaluation as a treatment option for pa-
tients with COVID-19.31,32  
 
Natural killer cells are the chief immune cells involved in 
cellular immunity to viruses.33,34 Their vital roles against 
viruses are highlighted in the heightened susceptibility of 
viral infections in persons with the rare congenital disor-
der of natural killer cell deficiency.34  Natural killer cells, 
very efficient in killing viruses without prior sensitiza-
tion, have been noted to be potent in killing: Poxviruses, 
Papillomaviruses, Herpesviruses, including the Cyto-
megalovirus and Influenzavirus.33,34 The effect of natural 
killer cells on coronaviruses is underscored in SARS, 
where a decreased number of natural killer cells was 
linked to the severity of the disease.35 A similar observa-
tion has recently been noted in patients with COVID-19 
with improved numbers of natural killer cells seen upon 
recovery after treatment with antiviral therapy, chloro-
quine, antibiotics and interferon.36 Natural killer cell ther-
apy is under evaluation for the management of COVID-
19.37   
 
Antibodies are another product of the immune system 
that is very potent against viruses and efficiently prevent 
and resolve viral infections.38,39 Antibodies generally 
neutralize free circulating viruses, a potent way of pre-
venting viral infection by preventing them from gaining 
access to target cells.38,39 Another way antibodies destroy 
viruses or virally infected cells are via Fc-mediated cell 
destruction using complement activation or antibody-me-
diated natural killer cell destruction.38,39  The importance 
of antibodies against viruses is underscored in patients 
with severe antibody deficiency seen in Burton’s X-
linked agammaglobulinemia (XLA). Severe viral infec-
tions in these patients resolve upon treatment with high 
doses of intravenous immunoglobin G.39 Immunoglobins 
G, A and M are crucial in antiviral immunity.40 Immuno-
globin G appears pivotal in the recovery of persons with 
SARS and COVID-19.41,42 Production of immunoglobu-
lins M and G were found to have started by the second 
week of infection in persons with SARS. As expected, 
immunoglobulin M levels rapidly began to fall after at-
taining their peak levels within the first few weeks, dis-
appearing within months, while the immunoglobin G lev-
els remained high for months after achieving peak lev-
els.40 Consequently, immunoglobulin G is thought to be 
the predominant antibody in the immune response to 
SARS-CoV, as is known to occur in other viral infec-
tions.41 Intravenous immunoglobulin (IVIg), which is im-
munoglobulin G obtained  from several healthy adults, is 
also under evaluation for use as treatment in combination 
with other antiviral agents in patients with COVID-
19.43,44  Despite the fact that IVIg is most effective when 
obtained from persons who have recently recovered from 
COVID-19, IVIg from healthy persons without prior ex-
posure to COVID-19 has been successfully employed in 
the treatment of persons with COVID-19.44  
 
Malaria and Viral Comorbidity   
One of the ways to understand how acquired malaria im-
munity affects other pathogens like viruses are to under-
stand what happens in coinfections with malaria.45 In ma-
laria-endemic areas of the world, several viruses can in-
fect humans, making it theoretically and clinically possi-
ble for viral diseases and malaria to co-exist in a single 
patient.46 How these diseases interact with each other is 
an expression of the rather complex alteration of the im-
mune system they exert on the host, which affects their 
pathogeneses.46 For example, in a review of studies on 
malaria and HIV coinfection, pregnant women and chil-
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to the negative effects of each other, with malaria increas-
ing HIV viral load and HIV increasing malaria para-
sitemia.47  
 
A similar effect was seen in a study on malaria and Ep-
stein-Barr virus coinfection, which established that ma-
laria lowers antiviral immunity in some children resulting 
in uncontrolled growth of B lymphocytes leading to Bur-
kitt’s lymphoma. The Epstein-Barr virus can suppress 
anti-parasite immunity in some children resulting in non-
cerebral severe malaria.48 Malaria has also been known 
to antagonize Chikungunya virus in mice with coinfec-
tion.49 Studies of malaria and Ebola virus coinfection 
have yielded variable results with reports of increased 
survival in some patients and increased mortality risk in 
others.50,51,52 
 
A scan of the available literature on malaria and respira-
tory virus coinfections in malaria endemic areas show 
that respiratory viruses are common in these areas and 
include: Influenza virus, Rhinovirus, human Respiratory 
Syncytial Viruses and coronaviruses, among others.53,54, 
55,56 These studies, however, were focused on the preva-
lence, clinical presentation and transmission dynamics of 
the viruses and did not consider the immune interactions 
and alterations occasioned by these coinfections. Malaria 
is considered a strong immunomodulator and is believed 
to hold potential benefit in the treatment of certain dis-
eases.57 
 
Possible Relationships between Malaria-activated In-
nate Immunity and COVID-19 
It is an established fact that malaria is a potent immuno-
modulator of adaptive immunity9 and has more recently 
been shown to also activate innate immunity, inducing 
immunological memory similar to adaptive immun-
ity.58,59 This immunological memory of the innate im-
munity, capable of mounting swifter and more successful 
immune response against subsequent infections and also 
capable of providing cross protection, is called trained 
immunity.58,59 Trained immunity is a term used for the 
first time by Netea and colleagues in 2011,58 which ex-
plains the activation of innate immunity by certain vac-
cines like BCG60 and pathogens like malaria.61,62 
 
The immune response against malaria  involves innate 
immunity with natural killer cells, monocyte, macro-
phages, proinflamatory and anti-inflammatory cytokines 
as the major players.9,15,17 Thus, persons living in malaria 
endemic areas with malaria immunity acquired through 
repeated sub-patent infections, might possess trained im-
munity which can be beneficial in mounting successful 
immune response against other pathogens like SARS-
CoV-2.63  
Cross protection of trained immunity is highly likely be-
cause of the non-specific response of innate immunity, 
evident by BCG vaccination conferring protection 
against other pathogens aside Mycobacterium tuberculo-
sis.59,64 Therefore,  it is possible that those with malaria 
immunity possess trained immunity and have circulating 
primed innate cells like natural killer cells capable of 
mounting a prompt and successful response against 
SARS-CoV-2.63 Cellular actors involved in trained im-
munity; for example, the natural killer cells are swifter in 
the production cytokines effective against subsequent in-
fections.59  
 
Malaria activation of innate immunity produces not only 
trained immunity (hyperresponsiveness) but also toler-
ance (hyporesponsiveness).61 This tolerance ensures a 
minimum inflammatory response from innate immune 
cells like monocytes in persons with malaria immunity, 
curbing the harmful inflammatory effects responsible for 
severe malaria, common in those without malaria im-
munity.65 This tolerance activated by malaria can also be 
cross-protective as subsequent unrelated infections might 
not be met with intense inflammatory response, thereby 
protecting against severe diseases.66 It has been specu-
lated that this tolerance might be the reason for people 
living in malaria-endemic areas (and possessing malaria 
immunity) being protected against the severe inflamma-
tory response of COVID-19, the hallmark of  severe 
SARS-CoV-2 infection.66 
 
Taken together, while malaria influences adaptive im-
munity,9,11 its impact is felt more with the activation of 
innate immunity resulting in both trained immunity and 
immune tolerance61,62, both of which are beneficial in 
protecting against severe malaria and may offer cross-
protection against other diseases like COVID-19.63,66  
 
Possible Research Areas  
To answer the question posed by this review, studies need 
to be conducted among patients with COVID-19 who live 
in malaria-endemic areas. Acquired malaria immunity 
must be assessed both in patients with COVID-19 and 
among healthy individuals. All immune system compo-
nents characteristically seen in persons with acquired im-
munity for malaria, like natural killer cells, interferon (in-
terferon gamma and type 1interferon) and immunoglobin 
G, should be evaluated among symptomatic and asymp-
tomatic patients with COVID-19. The role of malaria-in-
duced trained immunity and immune tolerance in patients 
with COVID-19 should also be investigated.  It is im-
portant to note that not all persons living in malaria-en-
demic areas have acquired malaria immunity.67 Some 
might have lost the immunity or failed to develop it due 
to inadequate exposure to Plasmodium as the levels of 
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The exposure risk is higher for persons with lower soci-
oeconomic status, especially those living in crowded or 
riparian communities, compared to those with higher so-
cioeconomic status living in well-organized urban cit-
ies.69,70 Additionally, the coordinated activities of na-
tional malaria control programs have progressively re-
duced the risks of malaria infection in many populations 
in malaria-endemic areas.67 The consequences of this re-




The COVID-19 pandemic presents a great opportunity 
for scientists, physicians and epidemiologists in malaria-
endemic areas to investigate the impact of endemic dis-
eases like malaria on COVID -19 and future epidemics.  
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